Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting primary and metastatic uveal melanoma with a G protein inhibitor.

The Journal of biological chemistry - 1 Jan 2000

Onken Michael D, Makepeace Carol M, Kaltenbronn Kevin M, Choi Joelle, Hernandez-Aya Leonel, Weilbaecher Katherine N, Piggott Kisha D, Rao P Kumar, Yuede Carla M, Dixon Alethia J, Osei-Owusu Patrick, Cooper John A, Blumer Kendall J

Abstract excerpt

Uveal melanoma (UM) is the most common intraocular tumor in adults. Nearly half of UM patients develop metastatic disease and often succumb within months because effective therapy is lacking. A novel therapeutic approach has been suggested by the discovery that UM cell lines driven by mutant constitutively active Gq or G11 can be targeted by FR900359 (FR) or YM-254890, which are bioavailable, selective inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Depsipeptides
Share to GTP-Binding Protein alpha Subunits, Gq-G11

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Peptides, Cyclic

Share to Uveal Melanoma

Share to Uveal Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 33577798
DOI: 10.1016/j.jbc.2021.100403
PMCID: PMC7948511

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting primary and metastatic uveal melanoma with a G protein inhibitor.PMID 33577798Read ↗

Targeting Oncogenic Gαq/11 in Uveal MelanomaSemantic proximity Read ↗

Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma.Semantic proximity Read ↗

Protein Kinase Signaling Networks Driven by Oncogenic Gq/11 in Uveal Melanoma Identified by Phosphoproteomic and Bioinformatic Analyses.Semantic proximity Read ↗

Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.Semantic proximity Read ↗

Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.Semantic proximity Read ↗

Gq/G11 oncogenic mutations promote PD-L1 expression and suppress tumor immunity.Semantic proximity Read ↗

Research in practice: Therapeutic targeting of oncogenic GNAQ mutations in uveal melanoma.Semantic proximity Read ↗

Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.Semantic proximity Read ↗

GNAQ and GNA11 mutations in uveal melanoma.Semantic proximity Read ↗

Functional characterization of uveal melanoma oncogenes.Semantic proximity Read ↗

Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.Semantic proximity Read ↗

Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.